What is inclusion body myositis?

Inclusion Body Myositis (IBM) is a rare, progressive muscle disease characterized by chronic muscle inflammation and weakness. It is the most common acquired muscle disease in adults over 50, affecting approximately 20,000 people in the United States.

Sporadic IBM (sIBM), the most common form, is NOT inherited — it occurs randomly. However, about 67% of patients carry a specific HLA gene combination that makes them genetically susceptible. Hereditary Inclusion Body Myopathies (hIBM) are a separate group of genetic muscle diseases.

Is there a cure for IBM?

As of 2026, there are no FDA-approved treatments specifically for IBM. The disease is notoriously resistant to corticosteroids and immunosuppressive drugs. Physical therapy and adaptive strategies are the mainstay of management. Active research is underway with promising clinical trials.

Does IBM qualify for disability benefits?

Yes. IBM is listed under Section 11.15 (Disorders of the Peripheral Nervous System) in the SSA Blue Book for Social Security Disability Insurance (SSDI). The IBM Functional Rating Scale can support your application.

What exercises are safe with IBM?

Walking, aquatic therapy, light resistance training, balance training, and hand/finger exercises are all recommended for IBM patients. Start slowly, build over 6-12 weeks, and consult with a physical therapist who understands myositis.

Why is IBM often misdiagnosed?

IBM is frequently misdiagnosed as polymyositis, normal aging, fibromyalgia, ALS, or sarcopenia. The average diagnostic delay is 5-10 years from symptom onset because IBM shares symptoms with more common conditions.

New Study Links Overactive IL-6 Inflammation in IBM Muscle to a Pathway Trials Are Already Targeting

Inflammation is a defining feature of IBM, but it is also poorly understood: patients often have no obvious signs of inflammation in standard blood tests, and the immune system seems to stay active in the muscle even when it should calm down. A new study helps explain why — and it points to a pathway that drug developers are already studying.

What the Researchers Did

Researchers at the University Medical Centre Ljubljana in Slovenia, publishing July 21, 2026 in the peer-reviewed journal Arthritis Research & Therapy, set out to measure how active the IL-6 (interleukin-6) pathway really is in idiopathic inflammatory myopathies (IIM) — the family of autoimmune muscle diseases that includes IBM.

IL-6 is often described as a master alarm signal of the immune system. When it binds to its receptor, it switches on a signaling cascade inside cells called the JAK/STAT pathway, which tells immune cells to stay switched on and muscles to become inflamed.

The team did two things. First, they looked at muscle gene-expression data from patients with IIM (including IBM) and healthy controls to see how active the IL-6/JAK/STAT3 pathway was in muscle tissue. Second, they took blood samples from 51 patients with IIM and 32 healthy controls and measured IL-6 levels, its soluble receptor, and antibodies that naturally block IL-6. They also used a laboratory assay to measure how strongly the patients' blood actually drives IL-6 signaling.

What They Found

Muscle tissue from patients showed clear enrichment of IL-6/JAK/STAT3 signaling across all disease subtypes — including IBM — compared with healthy muscle.

In the blood, IL-6 levels were higher in patients than in healthy controls. But the more striking finding was this: when they measured overall IL-6 signaling activity directly, the patients' blood drove markedly higher IL-6 signaling than controls — even when individual IL-6 levels looked similar. That enhanced signaling persisted even in patients already on treatment.

The researchers also found that patients had lower levels of naturally occurring antibodies that normally neutralize IL-6. In the lab, those antibodies showed the ability to block IL-6 activity. This suggests the body's own braking system for this inflammatory pathway is weakened in people with these diseases.

Perhaps most importantly for patients, higher IL-6 signaling activity in newly diagnosed patients showed a trend toward weaker muscle strength — an early hint that this pathway may be linked to the muscle damage itself.

What This Means for IBM Patients

Why does this matter? It offers a concrete explanation for a frustrating puzzle: IBM is clearly an inflammatory disease, yet simple blood tests often look unremarkable. This study shows that the real problem may not be the level of IL-6 itself, but the whole environment around it — the signaling is amplified even when the raw numbers look normal.

It also points to a pathway, JAK/STAT, that is already a focus of IBM research. JAK inhibitors — a class of drugs that block this exact signaling cascade and are already approved for other autoimmune conditions — are being studied in IBM. Findings like this one help explain why targeting that pathway is worth testing.

One note of caution: this was a study of IL-6 pathway biology across inflammatory myopathies, not a clinical trial of any treatment. IL-6 signaling was increased across the whole IIM group, and the muscle-strength connection was a statistical trend rather than a proven effect. But for patients, it is meaningful progress to see researchers pinning down the specific molecular pathways driving muscle inflammation — because that is what new treatments are built from.

Source

• Srpčič A, Urzi F, Ogrič M, et al. "Dysregulated IL-6 pathway activity in idiopathic inflammatory myopathies." Arthritis Research & Therapy. 2026 Jul 21. https://doi.org/10.1186/s13075-026-03867-x

New Study Links Overactive IL-6 Inflammation in IBM Muscle to a Pathway Trials Are Already Targeting

What the Researchers Did

What They Found

What This Means for IBM Patients

Source

Tags

Related Reading

More Research